X

Trial Profile

A multi-center investigator-initiated Phase 1 trial evaluating the safety and efficacy of GC027 for the treatment of adults with r/r T-ALL

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 May 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 027 (Primary)
Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Gracell Biotechnology

Most Recent Events

09 May 2021 New trial record
10 Apr 2021 According to Gracell Biotechnologies media release, updated data from this trial presented in an oral and e-poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
10 Apr 2021 Results (data cut off:4 Feb 2021) published in the Gracell Biotechnologies Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com